Results 151 to 160 of about 29,074 (242)

Design, validation, and functional impact of oligonucleotides for multigene silencing in Alzheimer's disease. [PDF]

Mol Ther Nucleic Acids
Woffindale C, Riera NG, Wood MJA, Varela MA.   +3 more
europepmc   +1 more source

Bispecific Antibody MDX447 [PDF]

, 2020
openaire   +1 more source

Recent advances in bispecific antibody-drug conjugates for breast cancer therapy. [PDF]

Cancer Chemother Pharmacol
Ji X, Yang Y, Ma C, Huang W, Guo S, Wang L, Zheng H, Wu X.   +7 more
europepmc   +1 more source

Application and Challenges of Chimeric Antigen Receptor T Cell Therapy in Systemic Rheumatic Diseases and Autoimmune Disorders

MedComm, Volume 7, Issue 4, April 2026.
CAR‐T cell therapy in systemic rheumatic diseases and autoimmune disorders. (This figure was created using BioRender.com.) ABSTRACT Chimeric antigen receptor T (CAR‐T) cell therapy, originally developed for hematologic malignancies, has emerged as a transformative candidate for systemic rheumatic diseases and autoimmune disorders (AIDs).
Zhidan Fan, Li Zhang, Haiguo Yu
wiley   +1 more source

Extracellular and Membrane Protein: Structure, Biological Functions, Diseases, and an Emerging Modality for Drug Discovery

MedComm, Volume 7, Issue 4, April 2026.
Targeted protein degradation represents a paradigm shift from traditional protein inhibition to complete protein elimination. This is achieved through three main strategies for degrading extracellular and membrane proteins: recruitment of cell‐surface LTRs, engagement of intracellular proteins, and receptor‐independent mechanisms.
Mengqing Zhao, Wenhao Yin, Jianjian Han, Huimin Wang, Zheng Liu, Lilong Liu, Wuxiang Mao   +6 more
wiley   +1 more source

Cutaneous Toxicities Associated With Amivantamab in Patients With Non‐Small Cell Lung Cancer: A Systematic Review

International Journal of Dermatology, EarlyView.
Ioannis‐Alexios Koumprentziotis, Aikaterini Bakella, Antonis Tsimpidakis, Alexander Stratigos, Vasiliki Nikolaou   +4 more
wiley   +1 more source

Factors Affecting Immune Reconstitution Post‐Allogeneic HSCT in Children: The Case for an Individualized Approach to Vaccination

European Journal of Haematology, Volume 116, Issue 4, Page 336-349, April 2026.
ABSTRACT Allogeneic hematopoietic stem cell transplantation (HSCT) is increasingly used to treat malignant and non‐malignant diseases. Following allogeneic HSCT, patients are particularly vulnerable to vaccine‐preventable diseases (VPD) because conditioning depletes immune cells, including memory cells.
Hélène Buvelot, Frederic Baleydier, Laure Pittet, Geraldine Blanchard‐Rohner   +3 more
wiley   +1 more source

Editorial: Bispecific antibodies and their conjugates in solid tumors and hematological malignancies. [PDF]

Front Immunol
Püsküllüoğlu M, Pacholczak-Madej R.
europepmc   +1 more source

Beyond PD‐1: Mechanisms of Resistance to Checkpoint Blockade in Classical Hodgkin Lymphoma and Next‐Generation Immune Strategies

European Journal of Haematology, Volume 116, Issue 4, Page 357-367, April 2026.
ABSTRACT PD‐1 inhibitors have reshaped the treatment landscape of classical Hodgkin lymphoma, yet a substantial proportion of patients exhibit primary or acquired resistance driven by tumor‐intrinsic alterations, immunosuppressive microenvironmental signals, metabolic constraints, and EBV‐mediated modulation.
Santino Caserta, Enrica Antonia Martino, Mamdouh Skafi, Maria Eugenia Alvaro, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

Therapeutic Antibodies in Hematology: Advances in Malignant and Non-Malignant Disorders. [PDF]

Cells
Yasui H, Idogawa M, Ishida T, Imai K.
europepmc   +1 more source